top of page

OncoGenesys: Genesis for Oncology Patients

Pioneering next-generation cancer treatments on the foundations of adaptive immunity. 

OUR SERVICES

Pre-clinical drug testing and advanced omics data analytics tailored to accelerate cancer research.

OUR SCIENCE

A three-stage innovation pipeline: target discovery, drug development, and preclinical testing.

WHO WE ARE

A multidisciplinary team with expertise in immunology, biology, chemistry, and data science.

paniero90_Futuristic_biotech_concept_glowing_immune_cells_and_e86ff069-5f10-4860-9214-d3f7

Over 3 million cancer patients each year face tumors that do not respond to immunotherapy.

More than $60 billion is spent annually on immunotherapies that ultimately fail to benefit patients.

Up to 70% of cancer patients lose their lives following resistance or relapse.

OUR COLLABORATORS

NovaMlong.png
footer-logo-new.png
bottom of page